IFN-γ blockade also has a key role in treating hemophagocytic lymphohistiocytosis (HLH), and HLH mouse models show that IFN-γ blockade has better survival outcomes compared to blockade of other cytokines (14–18). This evidence concerns the gene IFNG and hemophagocytic syndrome.